Get started
Author

Franziska Mergel

Observed names: F Mergel, F. Mergel, F., Mergel
ORCID: 0000-0002-0966-946X
Observed ORCID: 0000-0002-0966-946X
OpenAlex ID: A5007788533
The Clinical Relevance of the NATALEE Study: Application of the NATALEE Criteria to a Real-World Cohort from Two Large German Breast Cancer Centers
2023 · Henning Schäffler, Franziska Mergel, et al. · International Journal of Molecular Sciences · 38
PDF
The efficacy of sacituzumab govitecan and trastuzumab deruxtecan on stable and active brain metastases in metastatic breast cancer patients—a multicenter real-world analysis
2024 · D. Dannehl, D. Jakob, et al. · ESMO Open · 35
Detection of minimal residual disease and prediction of recurrence in breast cancer using a plasma-only circulating tumor DNA assay
2025 · W. Janni, B. Rack, et al. · ESMO Open · 33
Diagnosis, Therapy and Follow-up of Cervical Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry No. 032/033OL, May 2021) – Part 1 with Recommendations on Epidemiology, Screening, Diagnostics and Therapy
2022 · Matthias W. Beckmann, Frederik A. Stübs, et al. · Geburtshilfe und Frauenheilkunde · 30
PDF
Diagnosis, Therapy and Follow-up of Cervical Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry No. 032/033OL, May 2021) – Part 2 with Recommendations on Psycho-oncology, Rehabilitation, Follow-up, Recurrence, Palliative Therapy and Healthcare Facilities
2022 · Tanja Fehm, Frederik A. Stübs, et al. · Geburtshilfe und Frauenheilkunde · 23
PDF
Cervical intraepithelial neoplasia grade 3: development during pregnancy and postpartum
2022 · Frederik A. Stuebs, Franziska Mergel, et al. · Archives of Gynecology and Obstetrics · 16
PDF
The SURVIVE study: Liquid biopsy guided surveillance after intermediate- to high-risk early breast cancer.
2024 · Kerstin Pfister, Sophia Huesmann, et al. · Journal of Clinical Oncology · 15
The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21stcentury: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors
2025 · Tatjana Braun, Sophia Huesmann, et al. · PLoS ONE · 8
PDF
Study Protocol of SURVIVE HERoes (NCT06643585): Trastuzumab Deruxtecan for molecular relapse in HER2+/ Low early breast cancer with ctDNA positivity after primary therapy
2025 · Kerstin Pfister, Thomas W. P. Friedl, et al. · PLoS ONE · 7
PDF
Abstract PO4-19-01: The SURVIVE-HERoes trial – a secondary adjuvant treatment intervention study with trastuzumab-deruxtecan in patients with HER2 positive/HER2 low early breast cancer and a molecular relapse, based on a positive ctDNA result
2024 · Sophia Huesmann, Franziska Mergel, et al. · Cancer Research · 5
Will Minimal Residual Disease Monitoring Be Part of Routine Surveillance?
2025 · Kerstin Pfister, Henning Schäffler, et al. · Oncology Research and Treatment · 4
Abstract PO1-20-05: SURVIVE study – a multicenter, randomized, controlled phase 3 superiority trial, evaluating liquid biopsy guided intensified follow-up surveillance in women with intermediate-to high-risk early breast cancer
2024 · Franziska Mergel, Sophia Huesmann, et al. · Cancer Research · 4
Is Radiographic Aftercare Obsolete? How Testing Positive for ctDNA Can Be a Precedent for Late Relapse, Even in Low-Risk Hormone-Receptor-Positive Breast Cancer
2025 · Kerstin Pfister, Sophia Huesmann, et al. · International Journal of Molecular Sciences · 2
PDF
The SURVIVE study: Standard surveillance vs. intensified liquid biopsy-based surveillance in early breast cancer survivors.
2025 · Henning Schäffler, Sophia Huesmann, et al. · Journal of Clinical Oncology · 1
Do We Need Anthracyclines for Elderly Patients with Triple-Negative Breast Cancer?
2025 · Stefan Lukac, Visnja Fink, et al. · Breast Care · 1
The SURVIVE HERoes trial – a secondary adjuvant treatment intervention study with trastuzumab deruxtecan (Enhertu) in early breast cancer patients with HER2-positive/HER2-low tumors and molecular relapse
2024 · K. Pfister, T.W. P. Friedl, et al. · Geburtshilfe und Frauenheilkunde · 1
Abstract PO5-16-11: Novel antibody-drug-conjugates in clinical routine: adherence, efficacy and tolerability - real-world data from German breast centers
2024 · Henning Schäffler, Dominik Dannehl, et al. · Cancer Research · 1
Reasons for encounter and recommended interventions in an interprofessional integrative oncology counseling program in outpatient care: a mixed-methods analysis of 1,693 consultation letters
2026 · Andreas Schmitt, Regina Stolz, et al. · Frontiers in Medicine
PDF
Abstract PS5-07-28: The SURVIVE HERoes study NCT06643585: Targeting molecular relapse in breast cancer
2026 · K. Pfister, T. W. Friedl, et al. · Clinical Cancer Research
464eTiP The SURVIVE HERoes study: Targeting molecular relapse in breast cancer. A secondary adjuvant intervention study of trastuzumab deruxtecan versus SOC treatment in patients with HER2 positive or HER2 low early breast cancer and ctDNA positivity after primary therapy
2025 · K. Pfister, T.W.P. Friedl, et al. · Annals of Oncology
Ein atypischer Verlauf mit vaginaler Blutung und hCG-Anstieg
2025 · Andreas Rizos, Lara Schüttoff, et al. · Die Gynäkologie
The SURVIVE HERoes study: Targeting molecular relapse in breast cancer—A secondary adjuvant intervention study of trastuzumab deruxtecan versus SOC treatment in patients with HER2-positive or HER2-low early breast cancer and ctDNA positivity after primary therapy.
2025 · Kerstin Pfister, Thomas W. P. Friedl, et al. · Journal of Clinical Oncology
PDF
Ausgeprägtes Erysipel unter Pembrolizumab bei Triple Negativem mNBC: Fallbericht
2024 · J. Veta Darkovski, F. Mergel, et al. · Geburtshilfe und Frauenheilkunde
Sekundäre Syphilis der Zervix uteri mit pseudoneoplastischen Aspekten
2024 · F. Mergel, S. T. Huesmann, et al. · Geburtshilfe und Frauenheilkunde
Palliative unilaterale axilläre Lymphonodektomie Level I-III zum Funktions- und Lebensqualitätserhalt bei einer Patientin mit metastasiertem Mammakarzinom
2024 · F. Mergel, K. Pfister, et al. · Geburtshilfe und Frauenheilkunde
Works count: 35
Citation count: 224
H-index: 8
I10-index: 7
Year
Topic
Type